Dr. Diaz on Response Rates for MSI-H and NTRK Fusions in GI Cancer

Video

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

MSI and NTRK fusions are present at a low level in multiple different tumor types. If found, the patient has dramatic responses that may be experienced for years, explains Diaz.

Further long-term research is needed to determine if these patients will achieve long-term survival or if they will progress, says Diaz.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine